HC Wainwright Cuts IN8bio (NASDAQ:INAB) Price Target to $8.00

IN8bio (NASDAQ:INAB) had its price objective cut by equities research analysts at HC Wainwright from $12.50 to $8.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

IN8bio Trading Up 5.4 %

NASDAQ INAB opened at $0.35 on Wednesday. IN8bio has a 12-month low of $0.22 and a 12-month high of $2.48. The company has a fifty day simple moving average of $0.30 and a two-hundred day simple moving average of $0.68. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.04. The stock has a market cap of $16.37 million, a P/E ratio of -0.42 and a beta of -0.07.

Institutional Trading of IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp lifted its position in IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 851,280 shares of the company’s stock after purchasing an additional 251,600 shares during the quarter. Sigma Planning Corp owned about 1.82% of IN8bio worth $230,000 as of its most recent SEC filing. 92.05% of the stock is owned by hedge funds and other institutional investors.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.